¼¼°èÀÇ ÀÎÅ¥º£ÀÌÅÍ, ÈíÀÔ±â, È£Èí±â, ¼Ò»ý±â, ±âŸ È£Èí ±â±â ½ÃÀå
Incubators, Inhalators, Respirators, Resuscitators and Other Breathing Devices
»óǰÄÚµå : 1792952
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 08¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 278 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,183,000
PDF & Excel (Single User License) help
PDF & Excel º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÆÄÀÏ ³» ÅØ½ºÆ®ÀÇ º¹»ç ¹× ºÙ¿©³Ö±â´Â °¡´ÉÇÏÁö¸¸, Ç¥/±×·¡ÇÁ µîÀº º¹»çÇÒ ¼ö ¾ø½À´Ï´Ù. Àμâ´Â 1ȸ °¡´ÉÇϸç, Àμ⹰ÀÇ ÀÌ¿ë¹üÀ§´Â ÆÄÀÏ ÀÌ¿ë¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,550,000
PDF & Excel (Global License to Company and its Fully-owned Subsidiaries) help
PDF & Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ ¹× 100% ÀÚȸ»çÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÏ½Ç ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â 1Àδç 1ȸ °¡´ÉÇϸç, Àμ⹰ÀÇ ÀÌ¿ë¹üÀ§´Â ÆÄÀÏ ÀÌ¿ë¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

ÀÎÅ¥º£ÀÌÅÍ, ÈíÀÔ±â, È£Èí±â, ¼Ò»ý±â, ±âŸ È£Èí ±â±â ¼¼°è ½ÃÀåÀº 2030³â±îÁö 354¾ï ´Þ·¯¿¡ ´ÞÇÒ Àü¸Á

2024³â¿¡ 242¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â ÀÎÅ¥º£ÀÌÅÍ, ÈíÀÔ±â, È£Èí±â, ¼Ò»ý±â, ±âŸ È£Èí ±â±â ¼¼°è ½ÃÀåÀº 2024-2030³â ºÐ¼® ±â°£ µ¿¾È CAGR 6.6%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 354¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀΠõ½Ä ¾ÖÇø®ÄÉÀ̼ÇÀº CAGR 4.7%¸¦ ±â·ÏÇÏ¸ç ºÐ¼® ±â°£ Á¾·á±îÁö 119¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. COPD ¾ÖÇø®ÄÉÀÌ¼Ç ºÐ¾ß´Â ºÐ¼® ±â°£ µ¿¾È¿¡ CAGR 7.8%ÀÇ ¼ºÀåÀÌ Àü¸ÁµË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 66¾ï ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 10.0%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ ÀÎÅ¥º£ÀÌÅÍ, ÈíÀÔ±â, È£Èí±â, ¼Ò»ý±â, ±âŸ È£Èí ±â±â ½ÃÀåÀº 2024³â¿¡ 66¾ï ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ °æÁ¦ ´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 72¾ï ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ºÐ¼® ±â°£ÀÎ 2024-2030³â CAGRÀº 10.0%¸¦ ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖ°í, ºÐ¼® ±â°£ µ¿¾È CAGRÀº °¢°¢ 3.4%¿Í 6.3%·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 4.3%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

ÀÎÅ¥º£ÀÌÅÍ, ÈíÀÔ±â, È£Èí±â, ¼Ò»ý±â, ±âŸ È£Èí ±â±â ¼¼°è ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

»ý¸íÀ¯Áö¸¦ À§ÇÑ È£Èíº¸Á¶ÀåÄ¡°¡ ÁßȯÀÚ Ä¡·áÀÇ ±Ù°£ÀÌ µÉ ¼ö ÀÖÀ»±î?

ÀÎÅ¥º£ÀÌÅÍ, ÈíÀÔ±â, È£Èí±â, ÀΰøÈ£Èí±â ¹× °ü·Ã È£Èí ½Ã½ºÅÛ°ú °°Àº È£Èí º¸Á¶ ÀåÄ¡ÀÇ ¿ªÇÒÀº ÀÓ»ó ¹× ÀÀ±Þ ÀÇ·á ȯ°æ ¸ðµÎ¿¡¼­ ºñ¾àÀûÀ¸·Î Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±â¼úÀº ´õ ÀÌ»ó ´Ü¼øÇÑ º¸Á¶ µµ±¸°¡ ¾Æ´Ñ ´Ù¾çÇÑ È¯ÀÚÀÇ Æ¯¼º°ú »óÅ¿¡ µû¶ó »ý¸íÀ» À¯ÁöÇϱâ À§ÇÑ ±âº» ±â±â·Î °£Áֵǰí ÀÖ½À´Ï´Ù. ½Å»ý¾Æ ÁßȯÀڽǿ¡¼­ ÀÎÅ¥º£ÀÌÅÍ´Â ¹Ì¼÷¾Æ ¹× ÀúüÁß¾ÆÀÇ Ã¼¿Â Á¶Àý°ú °¨¿° °ü¸®¸¦ º¸ÀåÇϱâ À§ÇØ ÇʼöÀûÀÎ ±â±âÀÔ´Ï´Ù. ±â°üÁöÈ®ÀåÁ¦³ª ÄÚ¸£Æ¼ÄÚ½ºÅ×·ÎÀ̵带 Åõ¿©ÇÏ´Â ÈíÀÔ±â´Â õ½Ä, COPD, ¾Ë·¹¸£±â ¹ÝÀÀÀÇ Ä¡·á¿¡ Á¡Á¡ ´õ ¸¹ÀÌ »ç¿ëµÇ°í ÀÖ½À´Ï´Ù. ÀΰøÈ£Èí±â¿Í ±â°è½Ä ÀΰøÈ£Èí±â´Â ƯÈ÷ ÆÒµ¥¹Í »óȲÀ̳ª ¼ö¼ú ÈÄ È¸º¹±â µî ÀÚÀ² È£ÈíÀÌ ¼Õ»óµÈ ±Þ¼º È£Èí°ï¶õ ȯÀÚ °ü¸®¿¡¼­ ÇÙ½ÉÀûÀÎ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. ±¸±ÞÂ÷³ª ±¸±Þ¼¾ÅÍ¿¡¼­ ÀÚÁÖ »ç¿ëµÇ´Â ÀΰøÈ£Èí±â´Â ½ÉÁ¤Áö³ª È£ÈíÁ¤Áö ½Ã Á¤»óÀûÀΠȣÈí±â´ÉÀ» ȸº¹½Ã۴µ¥ ¸Å¿ì Áß¿äÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ±â±âµéÀº ¸¸¼ºÁúȯ °ü¸®¿Í ±Þ¼º±â ÁßÀç¿¡ ÇʼöÀûÀ̸ç, ÀÔ¿øÈ¯ÀÚ, ¿Ü·¡È¯ÀÚ, °¡Á¤°£È£ ÇöÀå¿¡¼­ÀÇ ´Ù°¢ÀûÀÎ Àû¿ëÀÌ °­Á¶µÇ°í ÀÖ½À´Ï´Ù. Àü ¼¼°èÀûÀ¸·Î È£Èí±âÁúȯÀÇ Áõ°¡, Àα¸ÀÇ °í·ÉÈ­, µµ½Ã Áö¿ªÀÇ ¿À¿°À¸·Î ÀÎÇØ È£Èí º¸Á¶ ÀåÄ¡´Â Çö´ë ÀÇÇп¡¼­ Ç×»ó Á¸ÀçÇÏ´Â °ÍÀÌ µÇ¾ú½À´Ï´Ù. °øÁß º¸°Ç ºñ»ó »óȲ¿¡¼­´Â È£Èí º¸Á¶ ÀåÄ¡ÀÇ È®À强°ú ½Å·Ú¼ºÀÌ »ý»ç¸¦ °¡¸¦ ¼ö Àֱ⠶§¹®¿¡ ±× Á߿伺ÀÌ ´õ¿í °­Á¶µË´Ï´Ù. º´¿ø¿¡¼­ Àç³­ ±¸Á¶ Áö¿ª¿¡ À̸£±â±îÁö ¸ðµç »óȲ¿¡¼­ ÀÌ·¯ÇÑ ±â±â´Â ȯÀÚÀÇ »ýÁ¸°ú ȸº¹À» À§ÇÑ È£Èí±âÀÇ ÇÙ½ÉÀ» Çü¼ºÇϰí ÀÖ½À´Ï´Ù.

¾î¶² ±â¼ú Çõ½ÅÀÌ È¿À²¼º°ú ȯÀÚ °á°ú¸¦ Çâ»ó½Ã۴°¡?

ÃÖ÷´Ü ±â¼ú Çõ½ÅÀº È£Èí º¸Á¶ ÀåÄ¡ÀÇ »óȲÀ» ÀçÁ¤ÀÇÇϰí, ¾ÈÀü¼º, È޴뼺, ÀÓ»ó È¿°úÀÇ ÇѰ踦 ¶Ù¾î³Ñ°í ÀÖ½À´Ï´Ù. °¡Àå ÁÖ¸ñÇÒ ¸¸ÇÑ ¹ßÀü Áß Çϳª´Â ÀÎÅ¥º£ÀÌÅÍ¿Í ÀΰøÈ£Èí±â ³»¿¡ ½º¸¶Æ® ¸ð´ÏÅ͸µ ½Ã½ºÅÛÀÌ ÅëÇÕµÇ¾î °£º´ÀÎÀÌ ½Ç½Ã°£À¸·Î Ȱ·Â ¡Èĸ¦ ÃßÀûÇϰí ħ½ÀÀû °³ÀÔ ¾øÀÌ µ¥ÀÌÅÍ ±â¹Ý ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖ°Ô µÈ °ÍÀÔ´Ï´Ù. ¿¹¸¦ µé¾î, ÃֽŠÀÎÅ¥º£ÀÌÅÍ´Â ½Å»ý¾Æ¿¡°Ô °¡Àå ¾ÈÀüÇÑ È¯°æÀ» º¸ÀåÇϱâ À§ÇØ ¹Ì±âÈÄ Á¦¾î, ÅÍÄ¡¸®½º ¸ð´ÏÅ͸µ, ½Àµµ Á¶Àý ±â´ÉÀ» °®Ãß°í ÀÖ½À´Ï´Ù. ÈíÀԱ⵵ ÁøÈ­ÇÏ¿© µðÁöÅÐ ¿ë·® Ä«¿îÅÍ, ºí·çÅõ½º Áö¿ø ¼øÀÀµµ ÃßÀû±â, À½¼º ¾È³»¸¦ ÅëÇÑ »ç¿ë ¼³¸í±îÁö žÀçÇÏ¿© ¸¸¼º È£Èí±âÁúȯ ȯÀÚ°¡ º¸´Ù È¿°úÀûÀ¸·Î Ä¡·á¸¦ °ü¸®ÇÒ ¼ö ÀÖµµ·Ï µµ¿ÍÁÝ´Ï´Ù. È£Èí±â´Â ÇöÀç ȯÀÚÀÇ Çǵå¹é¿¡ µû¶ó ȯ±â ¼³Á¤À» ÀÚµ¿À¸·Î Á¶Á¤ÇÏ´Â ÀûÀÀ ¾Ë°í¸®ÁòÀ» °®Ãß°í ÀÖ¾î ÇÕº´ÁõÀ» ÃÖ¼ÒÈ­Çϰí ÀÇ·áÁøÀÇ ºÎ´ãÀ» ÁÙÀÔ´Ï´Ù. °í±Þ ¾Ð·Â Á¦¾î ±â´ÉÀ» °®Ãá ¹èÅ͸® ±¸µ¿½Ä °æ·® ÀΰøÈ£Èí±â´Â ¿ø°ÝÁö ¹× ÀÌ¼Û È¯°æ¿¡¼­ÀÇ ÀÀ±Þ ´ëÀÀ È¿À²À» Çâ»ó½Ãŵ´Ï´Ù. ÀÌ·¯ÇÑ ±â±â Áß »ó´ç¼ö´Â ÇöÀç ÅÍÄ¡½ºÅ©¸° ÀÎÅÍÆäÀ̽º¿Í Ŭ¶ó¿ìµå¿¡ ¿¬°áµÈ µ¥ÀÌÅÍ Æ÷ÅÐÀ» °®Ãß°í ÀÖÀ¸¸ç, ȯÀÚÀÇ °á°ú¸¦ Áß¾Ó ÁýÁᫎ ÀüÀÚ ÀÇ·á ±â·Ï¿¡ ¿¬°áÇÒ ¼ö ÀÖ½À´Ï´Ù. Á¦Á¶¾÷ü´Â ¶ÇÇÑ Ç×±Õ ¼ÒÀç, °í±Þ HEPA ÇÊÅÍ, ¼ÒÀ½ °¨¼Ò ±â¼úÀ» »ç¿ëÇÏ¿© À§»ý°ú ȯÀÚÀÇ Æí¾ÈÇÔÀ» Çâ»ó½Ãŵ´Ï´Ù. ¿ø°ÝÀÇ·á¿Í ÀçÅÃÀÇ·á°¡ Áõ°¡ÇÔ¿¡ µû¶ó ÀÛ°í »ç¿ëÇÏ±â Æí¸®ÇÑ È£Èí±â¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖÀ¸¸ç, ÀÎü°øÇÐÀû µðÀÚÀΰú ¸ð¹ÙÀÏ ´ëÀÀÀ» À§ÇÑ Çõ½ÅÀÌ ¿ä±¸µÇ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±â¼ú ¹ßÀüÀº Ä¡·á °á°ú¸¦ °³¼±ÇÒ »Ó¸¸ ¾Æ´Ï¶ó »ç¿ëÀÚ °æÇèÀ» Çâ»ó½ÃÄÑ È¯ÀÚ¿Í ÀÇ·á ¼­ºñ½º Á¦°øÀÚ ¸ðµÎ°¡ ¿øÈ°ÇÏ°í ¾ÈÀüÇÑ Ä¡·á ¿©Á¤À» ÅëÇØ ÇýÅÃÀ» ´©¸± ¼ö ÀÖµµ·Ï ÇÕ´Ï´Ù.

°øÁß º¸°ÇÀÇ ÇÊ¿ä¿Í ÀÓ»óÀû ¿ä±¸´Â ¾î¶»°Ô ±â±â äÅÃÀ» ÃËÁøÇϰí Àִ°¡?

È£Èí±âÁúȯÀÇ ºÎ´ã Áõ°¡¿Í ÀÇ·á ¼­ºñ½º Á¦°ø ¸ðµ¨ÀÇ º¯È­´Â ÷´Ü È£Èí º¸Á¶ ÀåÄ¡¿¡ ´ëÇÑ ¼ö¿ä¸¦ Å©°Ô Çü¼ºÇϰí ÀÖ½À´Ï´Ù. õ½Ä, ¸¸¼º ±â°üÁö¿°, Æó¼¶À¯Áõ°ú °°Àº ¸¸¼º È£Èí±âÁúȯÀº ƯÈ÷ °í·ÉÈ­ Àα¸ Áý´Ü°ú »ê¾÷ °øÇØ ¹× ´ã¹è »ç¿ëÀÇ ¿µÇâÀ» ¹Þ´Â Áö¿ª¿¡¼­ ´õ¿í ¸¸¿¬Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ È¯ÀÚ ±ÞÁõÀ¸·Î ÀÎÇØ Á¢±Ù¼º, È¿°ú¼º, »ç¿ë ÆíÀǼºÀ» °®Ãá Ä¡·á ±â±â¿¡ ´ëÇÑ ¼ö¿ä°¡ ±ÞÁõÇϰí ÀÖ½À´Ï´Ù. ÀÎÅ¥º£ÀÌÅÍ´Â ¿µ¾Æ »ç¸Á·üÀÌ ³ôÀº ±¹°¡³ª ÀÓ»êºÎ °Ç°­ ÇÕº´ÁõÀ¸·Î ÀÎÇØ Á¶»êÀÌ Áõ°¡ÇÏ´Â ±¹°¡¿¡¼­ ¼ö¿ä°¡ ³ô½À´Ï´Ù. ÈíÀÔ±â´Â Àǻ簡 ¸¸¼º ȯÀڵ鿡°Ô Àå±â ÈíÀÔ ¿ä¹ýÀ» ó¹æÇÏ´Â °æ¿ì°¡ ¸¹¾ÆÁö¸é¼­ °¡Á¤¿ë ±â±â·Î ÀÚ¸® Àâ°í ÀÖ½À´Ï´Ù. °ú°Å¿¡´Â ÁßȯÀڽǿ¡ ±¹ÇѵǾú´ø È£Èí±â¿Í ÀΰøÈ£Èí±â°¡ ÀÌÁ¦´Â ¿Ü·¡ ȯ°æ, ƯÈ÷ ÁøÇ༺ ½Å°æ±ÙÀ°ÁúȯÀ» ¾Î°í Àִ ȯÀÚµéÀ» À§ÇØ °¡Á¤¿¡±îÁö ¹èÄ¡µÇ°í ÀÖ½À´Ï´Ù. COVID-19 ÆÒµ¥¹Í°ú °°Àº °øÁߺ¸°Ç ºñ»ó»çÅ´ ȣÈí±â ÀÎÇÁ¶óÀÇ ½É°¢ÇÑ °ÝÂ÷¸¦ µå·¯³Â°í, Á¤ºÎ¿Í ÀÇ·á ±â°üÀº ÀÌ·¯ÇÑ ±â±âÀÇ ºñÃà°ú ¾÷±×·¹À̵忡 ´ëÇÑ ÅõÀÚ¸¦ ´Ã¸®µµ·Ï Ã˱¸Çß½À´Ï´Ù. ±¸±Þ ¼­ºñ½º ¹× Àç³­ ´ëÃ¥ÆÀµµ ´ëÀÀ ´É·ÂÀ» °­È­Çϱâ À§ÇØ ÈÞ´ë¿ë ¼Ò»ý¼ú ŰƮ¿Í ÇöÀå ´ëÀÀ¿ë È£Èí±â ½Ã½ºÅÛÀ» ¿ì¼±¼øÀ§¿¡ µÎ°í ÀÖ½À´Ï´Ù. º¸Çè»ç ¹× Á¤Ã¥ ÀÔ¾ÈÀÚµéÀº Á¶±â È£Èí±â ÁßÀçÀÇ °¡Ä¡¸¦ ÀνÄÇϰí, ȯÀڵ鿡 ´ëÇÑ »óȯ ¹× Á¢±Ù¼ºÀ» È®´ëÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¼¼°è °Ç°­ ÀÌ´Ï¼ÅÆ¼ºê¿Í ºñ¿µ¸® ´Üü´Â È£Èí±â¸¦ ¼Ò¿ÜµÈ Áö¿ª¿¡ Á¦°øÇϱâ À§ÇØ ³ë·ÂÇϰí ÀÖÀ¸¸ç, ÀÌ¿¡ ´ëÇÑ Àνİú ¼ö¿ä¸¦ ³ôÀ̱â À§ÇØ ³ë·ÂÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±¤¹üÀ§ÇÑ ÀÓ»óÀû ÇÊ¿ä¿Í °øÁߺ¸°ÇÀû ¿ä±¸´Â ¼±Áø±¹°ú ½ÅÈï±¹ ½ÃÀå ¸ðµÎ¿¡¼­ È£Èíº¸Á¶±â¼úÀÇ Ã¤Åðú Áö¼ÓÀûÀÎ ±â¼ú Çõ½ÅÀ» °¡¼ÓÈ­Çϰí ÀÖ½À´Ï´Ù.

Àü ¼¼°è È£Èí±â ½ÃÀåÀÇ ¼ºÀåÀ» À̲ô´Â ¿äÀÎÀº ¹«¾ùÀϱî?

ÀÎÅ¥º£ÀÌÅÍ, ÈíÀÔ±â, È£Èí±â, ¼Ò»ý±â ¹× ±âŸ È£Èí±â ÀåÄ¡ ¼¼°è ½ÃÀåÀº Àα¸Åë°èÇÐÀû, °æÁ¦Àû, ±â¼úÀû ¿äÀÎÀÌ º¹ÇÕÀûÀ¸·Î ÀÛ¿ëÇÏ¿© ºü¸£°Ô ¼ºÀåÇϰí ÀÖ½À´Ï´Ù. ÁÖ¿ä ¿øµ¿·ÂÀº ¼¼°è Àα¸ÀÇ °í·ÉÈ­À̸ç, ³ëÀÎÀº ¿ø·¡ È£Èí±â ÇÕº´Áõ¿¡ °É¸®±â ½±°í Àå±âÀûÀΠȣÈí º¸Á¶°¡ ÇÊ¿äÇÕ´Ï´Ù. ƯÈ÷ ¾Æ½Ã¾ÆÅÂÆò¾ç°ú ¾ÆÇÁ¸®Ä« ÀϺΠÁö¿ªÀÇ µµ½ÃÈ­¿Í »ê¾÷È­´Â õ½Ä, Æó °¨¿°, ´ë±â ¿À¿°°ú °ü·ÃµÈ °Ç°­ ¹®Á¦ ¹ß»ý·ü Áõ°¡·Î À̾îÁö´Â ȯ°æÀû Á¶°ÇÀÇ ÇÑ ¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. ¹Î°£ ¹× °ø°ø ºÎ¹® ¸ðµÎ¿¡¼­ ÀÇ·áºñ ÁöÃâÀÌ Áõ°¡ÇÔ¿¡ µû¶ó º´¿ø°ú Ŭ¸®´ÐÀº ³ëÈÄÈ­µÈ ±â±â¸¦ ¾÷±×·¹À̵åÇÏ°í º¸´Ù »õ·Ó°í È¿À²ÀûÀÎ ½Ã½ºÅÛÀ» µµÀÔÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. ÀÌ·¯ÇÑ ¼ºÀåÀ» µÞ¹ÞħÇÏ´Â ¶Ç ´Ù¸¥ °­·ÂÇÑ ÈûÀº ÀçÅÃÀÇ·á¿¡ ´ëÇÑ °ü½ÉÀÇ Áõ°¡ÀÔ´Ï´Ù. ¸¸¼ºÁúȯÀ» ¾Î°í Àִ ȯÀÚµéÀº ÀÛ°í ÈÞ´ë °¡´ÉÇÑ È£Èí±â¸¦ »ç¿ëÇÏ¿© Àͼ÷ÇÑ È¯°æ¿¡¼­ °Ç°­°ü¸®¸¦ ÇÏ´Â °ÍÀ» ¼±È£ÇÕ´Ï´Ù. ¿ø°Ý ¸ð´ÏÅ͸µ ±â¼ú°ú ¿þ¾î·¯ºí ÀÇ·á±â±âÀÇ ±ÞÁõÀº ½Ç½Ã°£ ¸ð´ÏÅ͸µÀ» Á¦°øÇÏ°í º´¿ø ÀçÀÔ¿øÀÇ Çʿ伺À» ÁÙÀÓÀ¸·Î½á ÀÌ·¯ÇÑ Ãß¼¼¸¦ µÞ¹ÞħÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÀÇ·á±â°üÀÇ ÀÎ½Ä °³¼± Ä·ÆäÀÎÀº ÀÏ¹Ý ½Ã¹Îµé¿¡°Ô È£Èí±â °Ç°­ÀÇ Á߿伺¿¡ ´ëÇØ ±³À°Çϰí, ÀÌ·¯ÇÑ ±â±â¸¦ ÀÌ¿ëÇÑ Á¶±â Áø´Ü ¹× Ä¡·á·Î À̾îÁö°í ÀÖ½À´Ï´Ù. Á¤ºÎÀÇ ÀçÁ¤ Áö¿ø, ÀÇ·á °³Çõ, ÀϺΠ±¹°¡ÀÇ À¯¸®ÇÑ »óȯ Á¤Ã¥À¸·Î ÀÎÇØ ´õ ¸¹Àº »ç¶÷µéÀÌ ÀÌ·¯ÇÑ ±â±â¸¦ »ç¿ëÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. Á¦Á¶¾÷ü´Â ¶ÇÇÑ º´¿ø, ¾à±¹, E-Commerce Ç÷§Æû°ú Àü·«Àû ÆÄÆ®³Ê½ÊÀ» ¸Î¾î À¯ÅëÀ» È®ÀåÇÏ°í ¸¶Áö¸· 1¸¶ÀÏ ¹è¼ÛÀ» °­È­Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¿äÀεéÀÌ °áÇյǾî È£ÈíÀåÄ¡ ½ÃÀåÀÇ Áö¼ÓÀûÀÎ ¼ºÀåÀ» µÞ¹ÞħÇÏ´Â °ß°íÇÑ »ýŰ踦 Çü¼ºÇϰí ÀÖÀ¸¸ç, È£ÈíÀåÄ¡´Â Àü ¼¼°è Çö´ë ÀÇ·á ¼­ºñ½ºÀÇ ÇÙ½ÉÀ¸·Î ÀÚ¸®¸Å±èÇϰí ÀÖ½À´Ï´Ù.

ºÎ¹®

¿ëµµ(õ½Ä ¿ëµµ, COPD ¿ëµµ, Æó¼â¼º ¼ö¸é¹«È£ÈíÁõ ¿ëµµ, ±âŸ ¿ëµµ), ÃÖÁ¾ ¿ëµµ(ÇコÄÉ¾î ½Ã¼³ ÃÖÁ¾ ¿ëµµ, Á¦¾à ±â¾÷ ÃÖÁ¾ ¿ëµµ)

Á¶»ç ´ë»ó ±â¾÷ »ç·Ê

AI ÅëÇÕ

Global Industry Analysts´Â °ËÁõµÈ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AI ÅøÀ» ÅëÇØ ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ Çõ½ÅÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â LLM ¹× ¾÷°è °íÀ¯ÀÇ SLMÀ» Á¶È¸ÇÏ´Â ÀϹÝÀûÀÎ ±Ô¹üÀ» µû¸£´Â ´ë½Å ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ¹æ´ëÇÑ ¾çÀÇ ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»ç ¼ÒÀçÁö, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±âÁØÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¸ÅÃâ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº Ç϶ô, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû, °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

KSM
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Incubators, Inhalators, Respirators, Resuscitators and Other Breathing Devices Market to Reach US$35.4 Billion by 2030

The global market for Incubators, Inhalators, Respirators, Resuscitators and Other Breathing Devices estimated at US$24.2 Billion in the year 2024, is expected to reach US$35.4 Billion by 2030, growing at a CAGR of 6.6% over the analysis period 2024-2030. Asthma Application, one of the segments analyzed in the report, is expected to record a 4.7% CAGR and reach US$11.9 Billion by the end of the analysis period. Growth in the COPD Application segment is estimated at 7.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$6.6 Billion While China is Forecast to Grow at 10.0% CAGR

The Incubators, Inhalators, Respirators, Resuscitators and Other Breathing Devices market in the U.S. is estimated at US$6.6 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$7.2 Billion by the year 2030 trailing a CAGR of 10.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.4% and 6.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.3% CAGR.

Global Market for Incubators, Inhalators, Respirators, Resuscitators, and Other Breathing Devices - Key Trends & Drivers Summarized

How Are Life-Sustaining Respiratory Devices Becoming the Backbone of Critical Care?

The role of respiratory support devices such as incubators, inhalators, respirators, resuscitators, and related breathing systems has grown exponentially in both clinical and emergency care environments. These technologies are no longer seen as mere support tools but as foundational equipment for sustaining life across a wide range of patient demographics and conditions. In neonatal intensive care units, incubators have become essential for ensuring thermal regulation and infection control for premature or low-birth-weight infants. Inhalators, used for delivering bronchodilators and corticosteroids, are increasingly relied upon for the treatment of asthma, COPD, and allergic reactions. Respirators and mechanical ventilators have taken center stage in managing acute respiratory distress, especially during pandemics or post-surgical recovery, where autonomous breathing is impaired. Resuscitators, often used in ambulances and emergency rooms, are crucial for restoring normal respiratory function during cardiac or respiratory arrest. These devices are indispensable in both chronic disease management and acute interventions, highlighting their multifaceted application across inpatient, outpatient, and home care settings. The global rise in respiratory illnesses, aging populations, and urban pollution has made breathing assistance devices a constant presence in modern medicine. Their relevance is further underscored during public health emergencies, where the scalability and reliability of such equipment can mean the difference between life and death. In every setting from hospitals to disaster relief zones, these devices form the respiratory core of patient survival and recovery.

What Technological Innovations Are Enhancing Efficiency and Patient Outcomes?

Cutting-edge innovation is redefining the landscape of breathing support devices, pushing the boundaries of safety, portability, and clinical effectiveness. One of the most notable advancements has been the integration of smart monitoring systems within incubators and respirators, allowing caregivers to track vital signs in real time and make data-driven decisions without invasive intervention. For example, modern incubators are equipped with microclimate control, touchless monitoring, and humidity regulation features that ensure the safest environment for neonates. Inhalators have evolved to include digital dose counters, Bluetooth-enabled adherence trackers, and even voice-guided usage instructions, helping patients with chronic respiratory diseases manage their treatments more effectively. Respirators now come with adaptive algorithms that automatically adjust ventilation settings based on patient feedback, minimizing complications and reducing the burden on healthcare staff. Battery-operated, lightweight resuscitators with advanced pressure control features are improving emergency response efficiency in remote and transport settings. Many of these devices now feature touchscreen interfaces and cloud-connected data portals that link patient outcomes to centralized electronic health records. Manufacturers are also using antimicrobial materials, advanced HEPA filtration, and noise-reduction technology to improve hygiene and patient comfort. With the rise of telemedicine and home healthcare, demand for compact and user-friendly respiratory devices is increasing, prompting innovation in ergonomic design and mobile compatibility. These technological strides are not only improving therapeutic outcomes but are also enhancing user experience, ensuring that both patients and providers benefit from a seamless and safe care journey.

How Are Public Health Needs and Clinical Demands Driving Device Adoption?

The growing burden of respiratory diseases, coupled with changing healthcare delivery models, is significantly shaping the demand for advanced breathing support devices. Chronic respiratory illnesses such as asthma, chronic bronchitis, and pulmonary fibrosis are becoming more prevalent, especially in aging populations and regions affected by industrial pollution and tobacco use. This surge in cases has created a pressing need for accessible, effective, and user-friendly treatment devices. Incubators are in high demand in countries facing high infant mortality rates or where preterm births are on the rise due to maternal health complications. Inhalators are becoming household devices as doctors increasingly prescribe long-term inhalation therapy for chronic patients. Respirators and ventilators, once confined to intensive care units, are now being deployed in ambulatory settings and even homes, particularly for patients with progressive neuromuscular diseases. Public health emergencies such as the COVID-19 pandemic exposed critical gaps in respiratory infrastructure, prompting governments and healthcare institutions to increase investment in stockpiling and upgrading such devices. Emergency services and disaster preparedness teams are also prioritizing portable resuscitation kits and field-ready respiratory systems to enhance response capabilities. Insurance providers and policymakers are recognizing the value of early respiratory intervention, offering greater reimbursement and access to patients. Additionally, global health initiatives and non-profit organizations are working to provide breathing devices to underserved regions, amplifying awareness and demand. These wide-ranging clinical and public health needs are accelerating the adoption and continuous innovation of breathing support technologies across both developed and emerging markets.

What Factors Are Fueling the Global Expansion of the Respiratory Devices Market?

The global market for incubators, inhalators, respirators, resuscitators, and other respiratory devices is expanding rapidly due to a mix of demographic, economic, and technological influences. A key driver is the aging global population, which is inherently more susceptible to respiratory complications and requires long-term breathing assistance. Urbanization and industrialization, particularly in Asia-Pacific and parts of Africa, are contributing to environmental conditions that lead to higher incidences of asthma, lung infections, and air pollution-related health problems. Increased healthcare spending in both private and public sectors is enabling hospitals and clinics to upgrade outdated equipment and adopt newer, more efficient systems. Another powerful force behind this growth is the rising focus on home healthcare, where patients with chronic conditions prefer to manage their health in familiar environments using compact, portable breathing devices. The surge in remote monitoring technologies and wearable medical devices is supporting this trend by providing real-time oversight and reducing the need for hospital readmissions. Additionally, awareness campaigns by health organizations are educating the public about the importance of respiratory health, leading to early diagnosis and treatment using these devices. Government funding, healthcare reforms, and favorable reimbursement policies in several countries are further making these devices accessible to larger sections of the population. Manufacturers are also forming strategic partnerships with hospitals, pharmacies, and e-commerce platforms to broaden distribution and enhance last-mile delivery. The combination of these factors is creating a robust ecosystem that supports sustained growth in the breathing device market, positioning it as a cornerstone of modern healthcare delivery worldwide.

SCOPE OF STUDY:

The report analyzes the Incubators, Inhalators, Respirators, Resuscitators and Other Breathing Devices market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Application (Asthma Application, COPD Application, Obstructive Sleep Apnea Application, Other Applications); End-Use (Healthcare Settings End-Use, Pharmaceuticals Companies End-Use)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 41 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â